Tandem Diabetes Care, Inc. Overview
Pro stress-test →Tandem Diabetes Care is an insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems for diabetes management. The company's flagship products include the t:slim X2 insulin pump and the Tandem Mobi system, which feature proprietary Control-IQ+ technology that uses predictive algorithms to automate insulin delivery.
Strategic Profile
Pro stress-test →Tandem is the number one recommended insulin pump brand by people living with diabetes for multiple years, having established significant brand loyalty and trust. The company leverages interoperable technology with major CGM manufacturers like Dexcom and Abbott, positioning itself as a comprehensive diabetes management platform rather than a standalone device maker.
Competitive Landscape
Pro stress-test →Tandem faces competition from Medtronic (dominant market share with Guardian 4 sensor), Insulet (Omnipod tubeless alternative), and emerging players like Beta Bionics. However, Tandem maintains analyst consensus of "Buy" with 12-month price target of $24.35 representing 24.65% upside from latest prices. Tandem's proprietary algorithms and user-centric design differentiate it in this competitive space.
Industry Context
Tandem Diabetes Care, Inc. operates in Medical Device Manufacturing - Insulin Delivery Systems & Diabetes Technology.
Key facts
Founded: 2006 · Headquarters: San Diego, United States · Employees: 2,650 · Revenue: $940.2M · Market cap: $1.3B